SUBSCRIBE
SUBSCRIBE
Kate Goodwin

Kate Goodwin

Contributing Writer | News & Features

Kate Goodwin hails from a background primarily in marketing. A passion for health sciences and writing led her to the biopharma news world, and she’s never looked back. She’s been writing for BioSpace for more than two years with a focus on cutting edge research, Alzheimer’s disease and pediatrics. Her free time is filled by her husband, children, Beagles, books, crochet and creative writing. She can be reached at kate.goodwin@biospace.com.

Pictured: AbbVie Corporate Office/iStock, vzphotos
AbbVie’s Humira to Take Hit from Biosimilars, Next-Gen Therapies: Report
As biosimilars and next-generation treatments for Crohn’s disease enter the market, AbbVie will be knocked from its place of longtime dominance, contends data and analytics firm GlobalData.
September 8, 2023
 · 
3 min read
 · 
Kate Goodwin
Pictured: Roche tower in Basel, Switzerland
Drug Development
Roche Sees Return on $310M Investment with Alnylam’s Phase II Hypertension Win
The RNAi therapy, which the companies are co-developing and commercializing, reduced blood pressure in hypertensive patients with high cardiovascular risk by 15 mmHg over placebo.
September 7, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Moderna COVID-19 Vaccine/iStock, carmeng
Drug Development
Moderna Says Updated COVID-19 Vaccine is Effective Against Newer Variants
The vaccine maker reported new trial data confirming an 8.7 to 11-fold increase in neutralizing antibodies against circulating strains, including the highly watched BA.2.86, EG.5 and FL.1.5.1 variants.
September 6, 2023
 · 
1 min read
 · 
Kate Goodwin
Pictured: Building with an Illumina sign in front/
Business
Illumina Taps Agilent Exec as New CEO Amid Company’s Daunting Challenges
Former Agilent Technologies executive Jacob Thaysen will take the reins later this month replacing CEO Francis deSouza, who stepped down in June following a proxy fight with activist investor Carl Icahn.
September 5, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: A funnel of American cash/iStock, ardasa
Healthcare Industry Poised to Profit from New Alzheimer’s Treatments
In addition to massive revenues predicted for their developers, Leqembi—and possibly donanemab, if approved—should bring in substantial dollars to the healthcare industry.
September 5, 2023
 · 
7 min read
 · 
Kate Goodwin
Pictured: 3D rendering of antibody-drug conjugate/
Drug Development
BioNTech, DualityBio Move ADC into Phase III for HER2-Low Breast Cancer
The antibody-drug conjugate will be pitted against chemotherapy in a heavily treated breast cancer subpopulation, with hopes of challenging AstraZeneca and Daiichi Sankyo’s blockbuster Enhertu.
September 1, 2023
 · 
2 min read
 · 
Kate Goodwin
Facade of Novo Nordisk's office in Fremont, California
Deals
Novo Bolsters Obesity Pipeline with Potential $500M Embark Biotech Buy
This is the Danish company’s second obesity-focused acquisition in three weeks. Under the deal, Novo Nordisk receives the full rights to develop and commercialize Embark’s lead metabolic platform.
August 30, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Bristol Myers Squibb in NJ/iStock, arlut
FDA
BMS Gets FDA Label Expansion for Potential Mega Blockbuster Reblozyl
Bristol Myers Squibb announced Monday that Reblozyl is now approved as a first-line treatment for adults with anemia due to myelodysplastic syndromes who may require regular blood transfusions.
August 29, 2023
 · 
2 min read
 · 
Kate Goodwin
Novo Nordisk's corporate headquarters in Denmark
Drug Development
Novo Adds Another Cardio Win for Wegovy, Shows Benefits in Heart Failure
Wegovy’s highest dose significantly improved physical function and quality of life in obese patients with heart failure, according to results published Friday in The New England Journal of Medicine.
August 25, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Roche Diagnostics building in California
Drug Development
Roche’s Divarasib Scores Phase I Win in KRAS-Mutated Solid Tumors
Data suggests divarasib could be more potent than already approved KRAS inhibitors from Amgen and Mirati, but the study’s authors caution against cross-trial comparisons.
August 24, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Syringe Drawing Up Drug from Vial/iStock
Apellis Probe Points to Needle as Possible Cause of Eye Injection Side Effects
After identifying structural variations in the 19-gauge filter needle included in some eye injection kits, Apellis has advised doctors to only use 18-gauge kits already in circulation and that will be distributed.
August 23, 2023
 · 
2 min read
 · 
Kate Goodwin
External view of Boehringer Ingelheim's headquarters in Silicon Valley
Drug Development
Boehringer Initiates Phase III Obesity Trials, Seeks to Challenge Novo and Lilly
The German company on Thursday said it is launching three late-stage studies of its obesity drug candidate after the injectable showed up to 19% weight loss after 46 weeks in a mid-stage trial.
August 17, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Hand changing blocks from Plan A to B/iS
Drug Development
Design Therapeutics Stock Plunges Amid Redesign of Only Clinical Asset
Following injection site reactions in a Phase I study, the company is developing a new formulation for its Friedreich’s ataxia candidate setting the asset’s clinical progress back significantly.
August 15, 2023
 · 
2 min read
 · 
Kate Goodwin
Policy
Ultragenyx Sued by Henrietta Lacks’ Family in Second HeLa Cell Line Lawsuit
After reaching a settlement with Thermo Fisher earlier this month, the family of Henrietta Lacks is now suing Ultragenyx for its “unjust enrichment” using their matriarch’s immortal cell line.
August 11, 2023
 · 
2 min read
 · 
Kate Goodwin
Michael Vi/Getty Images, Mark Wildgust_Janssen Bio
Drug Development
J&J Snags FDA Approval for Second Multiple Myeloma Bispecific Antibody
Despite being heavily pretreated, patients on J&J’s Talvey saw a 73.6% overall response rate in a Phase II study, winning accelerated approval from the regulator.
August 10, 2023
 · 
2 min read
 · 
Kate Goodwin
Load More